We are international
Donate
TEXT SIZE   


ASH 2011: Dr. Richardson - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
12.07.11


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles